On the road to the optimal treatment of lupus nephritis: are we there yet?

Chan TM , Tse KC , Tang CS , Lai KM , Li FK. Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine . Lupus 2005; 14: 265-272 .

Mok CC , Ying KY , Tang S et al. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis . Arthritis Rheum 2004; 50: 2559-2568 .

Houssiau FA , Vasconcelos C , D’Cruz D et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide . Arthritis Rheum 2002; 46: 2121-2131 .

Ginzler E , Aranow C , Buyon J et al. A mulicenter study of mycophenolate mofetil (MMF) vs. intravenous cyclophosphamide (IVC) as induction therapy for severe lupus nephritis (LN): preliminary results . Arthritis Rheum 2003; 48: S647-S647 .

Contreras G , Pardo V , Leclercq B et al. Sequential therapies for proliferative lupus nephritis . N Engl J Med 2004; 350: 971-980 .

Austin HA , Klippel JH , Balow JE et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs . N Engl J Med 1986; 314: 614-619 .

Takada K , Arefayene M , Desta Z et al. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis . Arthritis Rheum 2004; 50: 2202-2210 .

Askanase A , Tseng C , Orentas Lein D et al. Pharmacogenetics, enzymatic phenotyping and metabolite monitoring to guide treatment with Imuran in SLE patients . Arthritis Rheum 2004; 50: S448-S448 .